Deep Learning Diagnostic and Risk-stratification for IPF and COPD

Launched by PEDIATRIC CLINICAL RESEARCH PLATFORM · Apr 7, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how artificial intelligence (AI) can help doctors diagnose certain serious lung diseases, specifically idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP), and chronic obstructive pulmonary disease (COPD). These conditions can be very challenging to manage, and getting a correct diagnosis early on is crucial for providing the right care and improving patients' quality of life. The study aims to see if AI can provide more accurate and quicker diagnoses compared to traditional methods.

To participate in this trial, you need to be over 18 years old and already diagnosed with one of the lung diseases mentioned. Control participants, who do not have these diseases but have other lung-related conditions, are also needed for comparison. If you join the study, you will undergo some tests that may include using AI technology to listen to your lungs and possibly lung ultrasound scans. This research could lead to better ways to diagnose and treat lung diseases in the future, benefiting many patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Written informed consent
• • age \> 18 years old.
• • patients with already-diagnosed IPF (group 1) prior to the consultation (index) date.
• • patients with already-diagnosed NSIP (group 2) prior to the consultation (index) date.
• • patients with already-diagnosed COPD (group 3) prior to the consultation (index) date.
• * Control subjects must be followed-up at the pulmonology outpatient clinic for:
• • 1. obstructive sleep apnoea.
• • 2. occupational lung diseases (miners, chemical workers, etc.).
• • 3. pulmonary nodules (considered benign after 2 years).
• Exclusion Criteria:
• • patients who cannot be mobilized for posterior auscultation.
• • patients known for severe cardiovascular disease with pulmonary repercussion.
• • patients known for a concurrent, acute, infectious pulmonary disease (e.g., pneumonia, bronchitis).
• • patients known for asthma.
• • patients known or suspected of immunodeficiency, alpha-1-antitrypsin deficit, and or under immunotherapy.
• • patients with physical inability to follow procedures.
• • patients with inability to give informed consent.